Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid to Collaborate with Non-Profit FIND on TB Tests for Developing Countries

NEW YORK, May 23 (GenomeWeb News) - Cepheid said today that it has entered into a collaboration with the non-profit Foundation for Innovative Diagnostics to develop a rapid molecular diagnostic test for tuberculosis.


The test, which will run on Cepheid's GeneXpert system, will detect TB mycobacteria in sputum and determine whether the organisms are drug resistant, the company said.


Cepheid researchers will collaborate with David Alland, a tuberculosis expert at the University of Medicine and Dentistry of New Jersey, on the development of the test, which will be designed to run on Cepheid's GeneXpert System.


FIND is based in Geneva and funded by the Bill and Melinda Gates Foundation. The organization's goal is to develop affordable diagnostic tests for diseases affecting underprivileged populations in developing countries.


According to data from the World Health Organization, TB caused approximately 1.7 million deaths in 2004.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.